Physician profile
Ruby W Pontello
NPI 1538162185
$7,425.55
in general payments reported to CMS, 2019-2025
25 companies · $2,903 in 2025
The $2,903 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $781 · 2023: $1,699 · 2024: $1,941 · 2025: $2,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,369 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,368.69 |
| Education | $174.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.90 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,008.23 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,007.45 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $849.72 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $723.82 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $578.53 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $352.14 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $290.36 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Indivior INC. | $205.66 | 2022-2025 | Sublocade, Perseris |
| Tris Pharma INC | $201.96 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Vanda Pharmaceuticals INC. | $192.18 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $188.04 | 2022-2025 | Trintellix |
| Lundbeck LLC | $149.48 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $140.99 | 2021-2025 | Loreev Xr, Gralise |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.88 | 2023-2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $101.71 | 2023-2025 | Wellbutrin, Aplenzin |
| Braeburn INC. | $63.55 | 2024-2025 | Brixadi |
| Corium, LLC | $49.35 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $46.06 | 2021-2023 | Jornay Pm |
| Noven Therapeutics, LLC | $45.34 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $24.45 | 2025 | Jornay Pm |
| Neuronetics, INC. | $22.47 | 2025 | Neurostar Tms Therapy System |
| Avanir Pharmaceuticals, INC. | $19.73 | 2022 | |
| Neos Therapeutics, LP | $15.79 | 2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Pontello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.